| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019380982 |
| P356 | DOI | 10.1038/MODPATHOL.3800729 |
| P698 | PubMed publication ID | 17361205 |
| P50 | author | Ronald Simon | Q40046025 |
| Luigi Tornillo | Q40856429 | ||
| P2093 | author name string | Luigi Terracciano | |
| Guido Sauter | |||
| Alessandro Lugli | |||
| Coya Tapia | |||
| Christian A Seemayer | |||
| Katharina Glatz | |||
| Martina Mirlacher | |||
| Hedvika Novotny | |||
| Hanspeter Spichtin | |||
| Milo Horcic | |||
| P2860 | cites work | A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment | Q81511454 |
| Trastuzumab trials steal show at ASCO meeting | Q81852806 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
| Trastuzumab: hopes and realities | Q34569899 | ||
| Tissue microarrays in drug discovery | Q35600009 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| Antitumor activity of HER-2 inhibitors | Q36211044 | ||
| Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial | Q38447818 | ||
| Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays | Q38452406 | ||
| Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma | Q38463184 | ||
| Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry | Q38463502 | ||
| HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization | Q38474353 | ||
| Her-2/neu oncogene amplification in clinically localised prostate cancer | Q42252556 | ||
| Prognostic factors and c-erbB-2 expression in non-small-cell lung carcinoma (c-erbB-2 in non-small cell lung carcinoma). | Q43888317 | ||
| HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? | Q44700955 | ||
| Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
| HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 | ||
| Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? | Q47906737 | ||
| Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression | Q47951353 | ||
| Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. | Q50775865 | ||
| Overexpression of her-2/neu in human prostate cancer and benign hyperplasia | Q58325256 | ||
| Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice | Q59567752 | ||
| Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer | Q73181572 | ||
| Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma | Q73243706 | ||
| Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas | Q73473432 | ||
| Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study | Q73783125 | ||
| Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay | Q77925384 | ||
| Prognostic relevance of gene amplifications and coamplifications in breast cancer | Q81085059 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 192-198 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Close association between HER-2 amplification and overexpression in human tumors of non-breast origin | |
| P478 | volume | 20 |
| Q54594739 | Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. |
| Q35399306 | Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms |
| Q43635123 | Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice |
| Q40886552 | Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays |
| Q35125725 | Epidermal growth factor receptor expression in urinary bladder cancer |
| Q28728860 | Fast and non-toxic in situ hybridization without blocking of repetitive sequences |
| Q33925506 | Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer |
| Q35495307 | HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain |
| Q37590066 | HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma |
| Q42431264 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing |
| Q34324291 | HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. |
| Q33517907 | HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy |
| Q41880900 | HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) |
| Q35670454 | Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. |
| Q49646394 | Immunophenotypic profile of tumor buds in breast cancer. |
| Q61852873 | Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors |
| Q57181580 | Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features |
| Q84069984 | Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients |
| Q54676467 | [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. |
| Q80606168 | [Molecular high throughput research in prostate carcinoma] |
| Q80941653 | [Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer] |
| Q54699857 | [Tumors of the urinary system. Current and old problems]. |
Search more.